FDA Grants Fast-track Status to Neovac’s IFNα Kinoid Vaccine for Lupus
The U.S. Food and Drug Administration (FDA) has granted fast-track status to Neovacs’ vaccine IFNα Kinoid, which is being evaluated as a treatment for systemic lupus erythematosus (SLE). The vaccine is aimed at blocking interferon alpha, or IFNa, a protein linked to lupus. The more IFNa that patients have, the…